The variant landscape
Each variant gets three separate questions: drug readthrough, DNA editing, or exact-restoration suppressor tRNA.
Small molecules
Point estimates screen broadly; interval lower bounds demand stronger support. Decay and residue tolerance narrow both.
Threshold sweep across 70,376 scoreable ClinVar nonsense variants
DARK BARS ARE STRONGER SUPPORT · More candidates means broader predicted reach, not proven benefit.
The midpoint alone leaves 2,757—more reach, weaker support.
Base editing
This is editor placement geometry—not efficiency, delivery, off-targets, or clinical eligibility.
Complete partition of 70,660 variants scoreable against BE4max + ABE7.10, SpCas9 NGG
GREEN MEANS A CANDIDATE PLACEMENT · Exact restoration is preferable; neither green segment demonstrates efficacy.
7,622 restore the exact amino acid.
Transcript survival
Adding start-proximal and long-exon exceptions reveals variants whose decay prediction depends on the rule.
A complete partition of 70,376 scoreable variants
GREEN KEEPS THE READTHROUGH ROUTE OPEN · Grey predicts RNA loss; orange marks rule-sensitive uncertainty.
One in five classifications changes. Both verdicts stay visible.
Suppressor tRNA
Each design adds only exact-restoration variants not reached by earlier designs.
Marginal variants per design, with cumulative coverage over the same scoreable denominator
Coverage is sequence logic, not therapeutic evidence. No suppressor tRNA in this project has a qualifying ribosome-profiling measurement.
Best starting portfolio, not evidence that either construct works or is safe.